What APS Pharma does

APS Pharma (operating as Acanthus Pharma Services Inc.) is a privately held, boutique Contract Development and Manufacturing Organization (CDMO) founded in 2021 and headquartered in Dundas, Ontario, Canada. The company provides custom synthetic chemistry, process development, GMP manufacturing at gram-to-kilogram scale, Chemistry Manufacturing and Controls (CMC) regulatory documentation support, and analytical method development services to pharmaceutical and biotechnology companies advancing small molecules and functional excipients through pre-clinical and early clinical development stages. In addition to its core service portfolio, APS Pharma operates a specialized Lipids product line offering customized cationic, ionizable, phospholipid, sterol, and stable isotope-labelled lipids used in lipid nanoparticle (LNP) drug delivery systems, including compounds relevant to mRNA vaccine and gene therapy applications.

The firm was founded and is led by co-founders Stefan Wodzinski, Ph.D. (CEO) and Jolanta Wodzinska, Ph.D. (Chief Scientific and Innovation Officer), who collectively bring approximately 48 years of industrial experience from Teva, Taro, Apotex Pharmachem, MIT, Hemosol, and ApoPharma. APS Pharma differentiates through a boutique, non-bureaucratic service model that emphasizes molecule-specific customization rather than standardized offerings, positioning the company as an agile partner for IND-enabling programs. Revenue is generated through project-based CDMO contracts and lipid product sales on a quote-based pricing model, with customer engagement conducted via direct business development outreach, website inquiry forms, and phone/email contact.

APS Pharma operates with a headcount of nine employees, serves customers in Canada and the United States, and has no disclosed institutional investors, funding rounds, partnerships, acquisitions, or named customers in the available record. The company maintains a minimal digital marketing footprint limited to a LinkedIn corporate page and its corporate website, and has no disclosed patents, regulatory actions, or public recognition awards.

Name

APS Pharma

Legal name

Acanthus Pharma Services Inc.

Website

https://acanthuspharma.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

APS Pharma (Acanthus Pharma Services Inc.) is a Canadian boutique CDMO founded in 2021 that provides custom synthesis, GMP manufacturing, CMC support, and specialized lipids for lipid nanoparticle drug delivery to pharmaceutical and biotechnology companies in North America.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Contract development manufacturing
• Pharmaceutical CDMO services
• Lipid nanoparticle synthesis
• GMP manufacturing chemistry
• Small molecule development

Headquarters

HQ city

Dundas

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. CDMO Services: Contract Development and Manufacturing services including development services, GMP manufacturing, CMC support, and analytical services. Revenue is generated through project-based contracts with pharmaceutical and biotech companies at various stages of drug development.
2. Lipid Products: Sale of customized lipid compounds for research and GMP applications, including catalog products and custom synthesis for drug delivery and vaccine development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

APS Pharma is a Contract Development and Manufacturing Organization (CDMO) that provides integrated chemistry, manufacturing, and analytical services to pharmaceutical and biotechnology companies. The company offers five interconnected service pillars: Development Services (GLP/non-GLP synthesis), GMP Manufacturing (gram to kilogram scale), CMC regulatory support, Analytical Services, and a customized Lipids product line for lipid nanoparticle drug delivery and vaccine applications.

Product overview

APS Pharma is a Contract Development & Manufacturing Organization (CDMO) offering an integrated service portfolio for pharmaceutical and biotech companies. The core offerings consist of five interconnected service pillars: Development Services (GLP/non-GLP chemistry and synthesis), GMP Manufacturing (scale-up from gram to kilogram), CMC Support (regulatory documentation and filings), Analytical Services (method development and validation), and a Lipids product line (customized lipids for lipid nanoparticle drug delivery and vaccine applications). These services are designed to support clients from pre-clinical through clinical development phases, with a focus on small molecule therapeutics and functional excipients for gene delivery.

Differentiator

Problem solved

Functional benefit

Products and services

• Development Services Full range of GLP and non-GLP services customized for product development, including lead optimization, advanced intermediate synthesis, library synthesis, fluorescent and biotin tagging, multi-gram synthesis, chemical route development, process optimization, custom synthesis, stable isotope labeling, radiolabeling, and controlled substance manufacturing for pharmaceutical and biotech clients.
• GMP Manufacturing GMP manufacturing services supporting pre-clinical to clinical development at gram to kilogram scale, with full documentation access for CMC regulatory filings. Targeted at pharmaceutical and biotech companies needing scalable manufacturing capacity.
• Chemistry Manufacturing & Controls (CMC) Support Regulatory framework support for communicating drug development approaches to regulators, including characterization reports, salt/polymorph screening, crystallization studies, impurity risk assessments, route scouting, and stability studies for IND submissions.
• Analytical Services Analytical infrastructure for IND submissions including method development, qualification, validation, stability studies, impurity mapping, and reference standard preparation for API quality control.
• Lipids Product Line Customized lipids for lipid nanoparticles used in drug delivery and vaccines, including DC-Cholesterol, NMDC-Cholesterol Iodide, DSPC, ALC-0315, SM-102, TT3, ALC-0159, and related lipid products available in R&D and GMP grades for gene therapy and vaccine developers.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Piramal Pharma Solutions: Global CDMO with capabilities in API, intermediates, drug product, and CMC services. Highly comparable on integrated small-molecule CDMO scope, though significantly larger in scale and geography.
• Sai Life Sciences: India-based small-molecule CRO/CDMO providing process chemistry, GMP manufacturing, and CMC services for pharma and biotech — closely aligned with Acanthus' pre-clinical to early-clinical scope.
• AGC Pharma Chemicals: Small-molecule CDMO offering process development, GMP manufacturing, and CMC support across pre-clinical to clinical scale — overlapping Acanthus' development-stage API/intermediates and CMC focus.
• Cambrex: Small-molecule API CDMO with deep capabilities in process development, scale-up, and analytical services — directly comparable service stack to Acanthus across the small-molecule CDMO value chain.
• Seqens: European CDMO offering custom synthesis, API manufacturing, and CMC services with strengths in small molecules and specialty intermediates — comparable to Acanthus' integrated chemistry and GMP offerings.
• Hovione: Portugal-headquartered small-molecule CDMO with strengths in API, particle engineering, and GMP scale-up for pre-clinical and clinical programs — directly comparable to Acanthus' integrated development-to-GMP service model.
• CordenPharma: CDM

Broad incumbents

• WuXi STA (WuXi AppTec): Major global CDMO offering end-to-end small-molecule development, manufacturing, and CMC across pre-clinical through commercial — broader incumbent competing for similar clients at greater scale.
• Croda Pharma (incl. Avanti Polar Lipids): Large specialty ingredients supplier that acquired Avanti Polar Lipids; supplies pharmaceutical-grade lipids including LNP components, overlapping directly with Acanthus' lipid product line.
• Patheon (Thermo Fisher Scientific): Large pharma services business within Thermo Fisher offering small-molecule API development, GMP manufacturing, and CMC — broader incumbent with overlapping service categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/aps-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about APS Pharma